James R. Empfield - Mar 4, 2022 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
EVP, Drug Discovery
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Mar 4, 2022
Transactions value $
-$1,567,665
Form type
4
Date filed
3/8/2022, 06:32 PM
Next filing
Mar 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $210K +25K +250% $8.40* 35K Mar 4, 2022 Direct
transaction XENE Common Shares Tax liability -$210K -6.69K -19.1% $31.42 28.3K Mar 4, 2022 Direct F1
transaction XENE Common Shares Sale -$564K -18.3K -64.68% $30.79 10K Mar 4, 2022 Direct F2
transaction XENE Common Shares Options Exercise $21K +2.5K +25% $8.40* 12.5K Mar 7, 2022 Direct
transaction XENE Common Shares Tax liability -$21K -695 -5.56% $30.23 11.8K Mar 7, 2022 Direct F3
transaction XENE Common Shares Options Exercise $270K +40K +338.84% $6.76* 51.8K Mar 7, 2022 Direct
transaction XENE Common Shares Tax liability -$271K -8.95K -17.28% $30.23 42.9K Mar 7, 2022 Direct F3
transaction XENE Common Shares Sale -$55.3K -1.81K -4.21% $30.62 41K Mar 7, 2022 Direct
transaction XENE Common Shares Sale -$948K -31K -75.64% $30.54 10K Mar 7, 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -25K -100% $0.00* 0 Mar 4, 2022 Common Shares 25K $8.40 Direct F5
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -2.5K -100% $0.00* 0 Mar 7, 2022 Common Shares 2.5K $8.40 Direct F5
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -40K -100% $0.00* 0 Mar 7, 2022 Common Shares 40K $6.76 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on March 3, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.21 to $31.0296, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 Represents the closing price of the Company's common shares on March 4, 2022 which was converted to a Canadian dollar amount for purposes of net settlement calculations.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.5161 to $30.6208, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F6 Vesting 25% on February 9, 2017 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.